Purpose: MYC gene rearrangements in diffuse large B-cell lymphoma (DLBCL) patients are associated with poor prognosis. Our aim was to compare patterns of 2[18F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (PET/CT) response in MYC + and MYC- DLBCL patients.
Methods: Interim PET/CT (I-PET) and end of treatment PET/CT (EoT-PET) scans of 81 MYC + and 129 MYC- DLBCL patients from 2 HOVON trials were reviewed using the Deauville 5-point scale (DS). DS1-3 was regarded as negative and DS4-5 as positive. Standardized uptake values (SUV) and metabolic tumor volume (MTV) were quantified at baseline, I-PET, and EoT-PET. Negative (NPV) and positive predictive values (PPV) were calculated using 2-year overall survival.
Results: MYC + DLBCL patients had significantly more positive EoT-PET scans than MYC- patients (32.5 vs 15.7%, p = 0.004). I-PET positivity rates were comparable (28.8 vs 23.8%). In MYC + patients 23.2% of the I-PET negative patients converted to positive at EoT-PET, vs only 2% for the MYC- patients (p = 0.002). Nine (34.6%) MYC + DLBCL showed initially uninvolved localizations at EoT-PET, compared to one (5.3%) MYC- patient. A total of 80.8% of EoT-PET positive MYC + patients showed both increased lesional SUV and MTV compared to I-PET. In MYC- patients, 31.6% showed increased SUV and 42.1% showed increased MTV. NPV of I-PET and EoT-PET was high for both MYC subgroups (81.8–94.1%). PPV was highest at EoT-PET for MYC + patients (61.5%).
Conclusion: MYC + DLBCL patients demonstrate aberrant PET response patterns compared to MYC- patients with more frequent progression during treatment after I-PET negative assessment and new lesions at sites that were not initially involved.
|Number of pages||10|
|Journal||European Journal of Nuclear Medicine and Molecular Imaging|
|Publication status||Published - Feb 2022|
Bibliographical noteon behalf of the HOVON imaging workgroup
Previously presented at the 33rd Annual Congress of the European Association of Nuclear Medicine – EANM’20 Virtual in the top rated oral presentation (TROP) Session: PET for Haematological Tumours
This work is financially supported by the Dutch Cancer Society (# VU 2018–11648).
J.J.E., A.I.J.A., J.E.H., F.C., B.d.K., S.S., D.d.J., S.E.W., G.J.C.Z., C.N.B. H.C.W.d.V., O.S.H., and R.B. declare no competing financial interests. P.J.L. received research funding from Takeda, Servier, and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, and Incyte. M.E.D.C. received research funding from Genmab, Gilead, Celgene, and BMS and received honoraria for advisory boards from Abbvie. J.M.Z. received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, and Roche.
© 2021, The Author(s).